Nanotechnology for Precision Delivery of Therapeutic and Imaging Agents – A Theranostic Approach
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: closed (10 April 2022) | Viewed by 4607
Special Issue Editor
Special Issue Information
Dear Colleagues,
Theranostic nanomedicine is an emerging field that combines the unique capabilities of nanotechnology with personalized medicine. The term “theranostics” was coined by combining diagnostic and therapeutic capabilities into a single agent. Over the last decade, researchers have investigated nanoparticle-based imaging and therapy separately, and only recently has the focus changed to NP-based theranostics. Even with the recent success of nanoparticles for the treatment of COVID-19, nanoparticle-based imaging and therapy are each struggling to advance into clinical trials. At the same time, nanoparticle-based theranostics are still in their early stages of development.
This Special Issue will provide insights into new drug delivery or imaging nanoparticles that could evolve into nanotheranostic platforms. Original research and reviews in the issue will focus on preclinical applications of delivery of therapeutic payloads and/or diagnostic probes in the context of cancer, cardiovascular and pulmonary diseases, and regenerative medicine.
Dr. Miguel Filipe Moreira Ferreira
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- theranostic
- nanomedicine
- imaging
- drug delivery
- preclinical
- cancer
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
